SCICLONE PHARMACEUTICALS INC - FORM 10-Q - EX-32.2 - SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER - May 10, 2011

Attached files

file filename
EX-10.1 - SHARE PURCHASE AGREEMENT - SCICLONE PHARMACEUTICALS INCdex101.htm
EX-32.1 - SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SCICLONE PHARMACEUTICALS INCdex321.htm
EX-10.2 - CHANGE IN CONTROL AGREEMENT - SCICLONE PHARMACEUTICALS INCdex102.htm
EX-10.6 - DIRECTOR SERVICES AGREEMENT - SCICLONE PHARMACEUTICALS INCdex106.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SCICLONE PHARMACEUTICALS INCdex311.htm
EX-10.5 - DIRECTOR SERVICES AGREEMENT - SCICLONE PHARMACEUTICALS INCdex105.htm
EX-10.4 - SECONDMENT CONTRACT - SCICLONE PHARMACEUTICALS INCdex104.htm
EX-10.3 - EMPLOYMENT AGREEMENT - SCICLONE PHARMACEUTICALS INCdex103.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION OF CHIEF FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex312.htm
10-Q - QUARTERLY REPORT ON FORM 10-Q - SCICLONE PHARMACEUTICALS INCd10q.htm

EXHIBIT 32.2

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Gary S. Titus, Senior Vice President, Finance and Chief Financial Officer, of SciClone Pharmaceuticals, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

 

(1) the Quarterly Report on Form 10-Q of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date: May 10, 2011      

/s/ Gary S. Titus

    Gary S. Titus
    Senior Vice President, Finance and Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to SciClone Pharmaceuticals, Inc. and will be retained by SciClone Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

SCICLONE PHARMACEUTICALS INC Reports